Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 3.41
PACB's Cash-to-Debt is ranked lower than
99.99% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. PACB: 3.41 )
Ranked among companies with meaningful Cash-to-Debt only.
PACB' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.41  Med: 8.22 Max: No Debt
Current: 3.41
Equity-to-Asset 0.51
PACB's Equity-to-Asset is ranked lower than
99.99% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. PACB: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
PACB' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.1  Med: 0.63 Max: 0.92
Current: 0.51
-2.1
0.92
Piotroski F-Score: 2
Altman Z-Score: -4.71
Beneish M-Score: -2.67
WACC vs ROIC
23.27%
-319.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -78.73
PACB's Operating Margin % is ranked lower than
99.99% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. PACB: -78.73 )
Ranked among companies with meaningful Operating Margin % only.
PACB' s Operating Margin % Range Over the Past 10 Years
Min: -65237.04  Med: -324.12 Max: -31.4
Current: -78.73
-65237.04
-31.4
Net Margin % -81.75
PACB's Net Margin % is ranked lower than
99.99% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. PACB: -81.75 )
Ranked among companies with meaningful Net Margin % only.
PACB' s Net Margin % Range Over the Past 10 Years
Min: -64965.19  Med: -323.03 Max: -34.16
Current: -81.75
-64965.19
-34.16
ROE % -87.78
PACB's ROE % is ranked lower than
99.99% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. PACB: -87.78 )
Ranked among companies with meaningful ROE % only.
PACB' s ROE % Range Over the Past 10 Years
Min: -272.85  Med: -88.81 Max: -46.42
Current: -87.78
-272.85
-46.42
ROA % -54.36
PACB's ROA % is ranked lower than
99.99% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. PACB: -54.36 )
Ranked among companies with meaningful ROA % only.
PACB' s ROA % Range Over the Past 10 Years
Min: -81.89  Med: -54.29 Max: -24.81
Current: -54.36
-81.89
-24.81
ROC (Joel Greenblatt) % -380.45
PACB's ROC (Joel Greenblatt) % is ranked lower than
99.99% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. PACB: -380.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PACB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1441.77  Med: -651.94 Max: -379.83
Current: -380.45
-1441.77
-379.83
3-Year Revenue Growth Rate 31.40
PACB's 3-Year Revenue Growth Rate is ranked lower than
73% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. PACB: 31.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PACB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 26 Max: 38.8
Current: 31.4
0
38.8
3-Year EBITDA Growth Rate -12.70
PACB's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. PACB: -12.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PACB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -48.35 Max: -12.7
Current: -12.7
3-Year EPS without NRI Growth Rate -13.00
PACB's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. PACB: -13.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PACB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -46.2 Max: -13
Current: -13
GuruFocus has detected 3 Warning Signs with Pacific Biosciences of California Inc $PACB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PACB's 10-Y Financials

Financials (Next Earnings Date: 2017-05-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PACB Guru Trades in Q1 2016

Paul Tudor Jones 18,800 sh (New)
Steven Cohen 706,500 sh (+11295.16%)
Lee Ainslie 7,561,268 sh (unchged)
Murray Stahl 12,000 sh (unchged)
Jim Simons 1,188,700 sh (-25.07%)
» More
Q2 2016

PACB Guru Trades in Q2 2016

Paul Tudor Jones 32,921 sh (+75.11%)
Lee Ainslie 7,820,808 sh (+3.43%)
Murray Stahl 12,000 sh (unchged)
Steven Cohen Sold Out
Jim Simons 404,064 sh (-66.01%)
» More
Q3 2016

PACB Guru Trades in Q3 2016

Lee Ainslie 9,095,663 sh (+16.30%)
Murray Stahl 12,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 374,900 sh (-7.22%)
» More
Q4 2016

PACB Guru Trades in Q4 2016

Paul Tudor Jones 78,879 sh (New)
Murray Stahl 12,000 sh (unchged)
Jim Simons Sold Out
Lee Ainslie 9,073,874 sh (-0.24%)
» More
» Details

Insider Trades

Latest Guru Trades with PACB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NAS:NTRA, NYSE:NVTA, NAS:LNTH, NAS:NVDQ, NYSE:ARA, OTCPK:BMLIF, NAS:NRCIA, NYSE:ENZ, NAS:VIVO, OTCPK:EPLYF, NAS:OXFD, NAS:ONVO, NAS:NEO, NAS:SRDX, NAS:RDNT, NAS:MGEN, NAS:QTNT, OTCPK:CBIS, NAS:HSKA, NAS:QDEL » details
Traded in other countries:P09.Germany,
Headquarter Location:USA
Pacific Biosciences of California Inc is engaged in design, development and manufacture of sequencing system to help scientists resolve genetically complex problems.

Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of innovative tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Pacific Biosciences' sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.

Guru Investment Theses on Pacific Biosciences of California Inc

Meridian Funds Comments on Pacific Biosciences of California Inc. - Mar 08, 2016

Pacific Biosciences of California Inc. (NASDAQ:PACB) is a leader in the field of next-generation gene sequencing technology. In October, the company unveiled the Sequel™ System, a gene-sequencing platform that is smaller and less expensive than the Pacific Bioscience’s former gene sequencer. This groundbreaking technology enables longer and more accurate reads of genomes, and is the result of collaboration with Roche, a health care company with interests in human in vitro diagnostics. Late in the period, Pacific Biosciences received a $20 million milestone payment from Roche for completing the project. We believe this new platform will enable the company to penetrate a larger portion of the broader sequencing market.







From the Meridian Small Cap Growth Fund fourth quarter commentary.



Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
PB Ratio 5.46
PACB's PB Ratio is ranked lower than
99.99% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. PACB: 5.46 )
Ranked among companies with meaningful PB Ratio only.
PACB' s PB Ratio Range Over the Past 10 Years
Min: 0.52  Med: 4.43 Max: 19.08
Current: 5.46
0.52
19.08
PS Ratio 3.81
PACB's PS Ratio is ranked lower than
99.99% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. PACB: 3.81 )
Ranked among companies with meaningful PS Ratio only.
PACB' s PS Ratio Range Over the Past 10 Years
Min: 1.99  Med: 7.19 Max: 27.11
Current: 3.81
1.99
27.11
EV-to-EBIT -5.82
PACB's EV-to-EBIT is ranked lower than
99.99% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. PACB: -5.82 )
Ranked among companies with meaningful EV-to-EBIT only.
PACB' s EV-to-EBIT Range Over the Past 10 Years
Min: -32.5  Med: -3.2 Max: 1.1
Current: -5.82
-32.5
1.1
EV-to-EBITDA -6.31
PACB's EV-to-EBITDA is ranked lower than
99.99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. PACB: -6.31 )
Ranked among companies with meaningful EV-to-EBITDA only.
PACB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -37.2  Med: -3.4 Max: 1.1
Current: -6.31
-37.2
1.1
Current Ratio 2.49
PACB's Current Ratio is ranked lower than
99.99% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. PACB: 2.49 )
Ranked among companies with meaningful Current Ratio only.
PACB' s Current Ratio Range Over the Past 10 Years
Min: 2.22  Med: 5.87 Max: 14.06
Current: 2.49
2.22
14.06
Quick Ratio 2.06
PACB's Quick Ratio is ranked lower than
99.99% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. PACB: 2.06 )
Ranked among companies with meaningful Quick Ratio only.
PACB' s Quick Ratio Range Over the Past 10 Years
Min: 1.92  Med: 5.5 Max: 13.74
Current: 2.06
1.92
13.74
Days Inventory 101.85
PACB's Days Inventory is ranked lower than
99.99% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. PACB: 101.85 )
Ranked among companies with meaningful Days Inventory only.
PACB' s Days Inventory Range Over the Past 10 Years
Min: 101.85  Med: 134.83 Max: 196.1
Current: 101.85
101.85
196.1
Days Sales Outstanding 39.49
PACB's Days Sales Outstanding is ranked lower than
99.99% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. PACB: 39.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
PACB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.52  Med: 35.57 Max: 74.35
Current: 39.49
20.52
74.35
Days Payable 56.71
PACB's Days Payable is ranked lower than
99.99% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. PACB: 56.71 )
Ranked among companies with meaningful Days Payable only.
PACB' s Days Payable Range Over the Past 10 Years
Min: 28.8  Med: 49.56 Max: 83.1
Current: 56.71
28.8
83.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.80
PACB's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. PACB: -11.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PACB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -380.3  Med: -11.1 Max: 0
Current: -11.8
-380.3
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 16.92
PACB's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. PACB: 16.92 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PACB' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.89  Med: 5.75 Max: 21.54
Current: 16.92
0.89
21.54
Price-to-Tangible-Book 5.46
PACB's Price-to-Tangible-Book is ranked lower than
99.99% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. PACB: 5.46 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PACB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.8  Med: 4.68 Max: 14.29
Current: 5.46
0.8
14.29
Price-to-Median-PS-Value 0.53
PACB's Price-to-Median-PS-Value is ranked lower than
98% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. PACB: 0.53 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PACB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.41  Med: 0.94 Max: 3.64
Current: 0.53
0.41
3.64
Earnings Yield (Greenblatt) % -17.18
PACB's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. PACB: -17.18 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PACB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -17.18  Med: 366.9 Max: 26741.7
Current: -17.18
-17.18
26741.7

More Statistics

Revenue (TTM) (Mil) $96.50
EPS (TTM) $ -0.86
Beta3.50
Short Percentage of Float16.93%
52-Week Range $3.75 - 10.66
Shares Outstanding (Mil)93.54

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 116 146
EPS ($) -0.86 -0.71
EPS without NRI ($) -0.86 -0.71
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PACB

Headlines

Articles On GuruFocus.com
Pacific Biosciences of California, Inc. Announces First Quarter 2017 Financial Results Apr 26 2017 
Pacific Biosciences of California, Inc. First Quarter 2017 Financial Results Call Apr 18 2017 
Meridian Funds Comments on Pacific Biosciences of California Inc. Mar 08 2016 
Weekly CEO Buys Highlight: CLR, CLMS, OPK, PACB, GAIN Dec 16 2013 
Weekly CEO Buys Highlight: OPK, PACB, CUBI, ARCP, RLYP Nov 25 2013 
Weekly CEO Buys Highlight: PHII, TUES, PACB, IPHI, WMC Dec 09 2012 
Weekly CEO Buys Highlight: PACB, AKS, EPIQ, GGS, TPGI Dec 02 2012 
Weekly CEO Buys Highlight: FFIN, STEC, MPO, PACB, TPGI Nov 25 2012 
Weekly CEO Buys Highlight: SUNS, PACB, GM, NPO, DGX Aug 11 2012 

More From Other Websites
Today's Research Reports on Biotech Stocks to Watch: Pacific Biosciences of California and BioMarin... Apr 28 2017
Edited Transcript of PACB earnings conference call or presentation 26-Apr-17 8:30pm GMT Apr 27 2017
Pacific Biosciences of California Reports Q1 Loss Due to Higher Costs Apr 27 2017
Here's Why Pacific Biosciences of California Is Sliding Today Apr 27 2017
Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes Apr 27 2017
Pacific Biosciences (PACB) Q1 Loss Wider than Estimated Apr 27 2017
Pacific Biosciences reports 1Q loss Apr 26 2017
Pacific Biosciences of California, Inc. Announces First Quarter 2017 Financial Results Apr 26 2017
Pacific Biosciences of California, Inc. – Value Analysis (NASDAQ:PACB) : April 25, 2017 Apr 25 2017
Pacific Biosciences of California, Inc. breached its 50 day moving average in a Bullish Manner :... Apr 24 2017
The Top Gene-Sequencing Stock to Buy in 2017 Apr 20 2017
Pacific Biosciences of California, Inc. First Quarter 2017 Financial Results Call Apr 18 2017
Pacific Biosciences (PACB): What Awaits in Q1 Earnings? Apr 17 2017
3 Big Reasons to Be Bullish on Biotech Stocks Apr 16 2017
Pacific Biosciences of California, Inc. breached its 50 day moving average in a Bearish Manner :... Apr 06 2017
Pacific Biosciences of California and Nymox Pharmaceutical Move Up On Bullish Product Environments Mar 30 2017
Pacific Biosciences of California's Recovery Continues Mar 29 2017
Pacific Biosciences of California, Inc. breached its 50 day moving average in a Bullish Manner :... Mar 24 2017
Pacific Biosciences (PACB) Up 5.5% Since Earnings Report: Can It Continue? Mar 07 2017
Biotech Premarket Movers: Pacific Biosciences of California, AMAG, Global Blood Therapeutics Feb 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)